Menu Back to 10th-Annual-Meeting-DIA-Japan-2013

Program Committee

  • Yasushi  Saito, MD, PhD
    Yasushi Saito, MD, PhD President
    Chiba University Hospital, Japan
  • Koichi  Miyazaki, MSc, RPh
    Koichi Miyazaki, MSc, RPh Senior Director, Regulatory Affairs Group, Asia Development Dept
    Daiichi Sankyo Co., Ltd., Japan
  • Koji  Ando
    Koji Ando Director
    Quintiles Transnational Japan K.K., Japan
  • Kasumi  Daidoji, MSc, RPh
    Kasumi Daidoji, MSc, RPh Associate Director, Drug Fostering & Evolution Coordination Dept, CMA HQs
    Eisai Co., Ltd., Japan
  • Satoru  Fukinbara, PhD
    Satoru Fukinbara, PhD Director, Data Science, Development Headquarters
    Ono Pharmaceutical Co., Ltd., Japan
  • Hirotaka  Inoue
    Hirotaka Inoue Head, Leading Changes Office, Japan Development & Medical Affairs
    GlaxoSmithKline K.K., Japan
  • Junichi  Koga, PhD, PMP
    Junichi Koga, PhD, PMP Corporate Officer, Global Head of Biologics, Biologics Oversight Function, R&D
    Daiichi Sankyo Co., Ltd., Japan
  • Yoshiko  Komuro, PhD
    Yoshiko Komuro, PhD Deputy Review Director, Office of New Drug II
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Koichi  Konno, PMP
    Koichi Konno, PMP Chief Exective
    PM Consulting Positive Intention, Japan
  • Rei  Maeda
    Rei Maeda Senior Regulatory Scientist, Surveillance & Epidemiology, Global Patient Safety
    Eli Lilly Japan K.K., Japan
  • Toshio  Maruyama
    Toshio Maruyama Manager (CMC), Regulatory Affairs Dept 2, Development & Medical Affairs Div
    GlaxoSmithKline K.K., Japan
  • Yoshihiro  Matsuda, PhD
    Yoshihiro Matsuda, PhD Deputy Division Director, Office of Standards and Guidelines Development
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Moriyuki  Miyasato, MBA
    Moriyuki Miyasato, MBA Senior Manager, Biostatistics Dept, Quantitative Science Div, R&D
    Janssen Pharmaceutical K.K., Japan
  • Takashi  Moritoyo, MD, PhD
    Takashi Moritoyo, MD, PhD Head, Phase 1 Unit, Clinical Research Support Center
    The University of Tokyo Hospital, Japan
  • Fumitaka  Nagamura, MD, PhD
    Fumitaka Nagamura, MD, PhD Professor
    The University of Tokyo, Japan
  • Kenji  Nagaya
    Kenji Nagaya General Manager, CDM and Biostatistics, Pharmaceutical Development Division
    Nippon Kayaku Co., Ltd., Japan
  • Nobumasa  Nakashima, PhD
    Nobumasa Nakashima, PhD International Planning Director (Pharmaceutical Affairs), Ministers Affairs
    Ministry of Health, Labour and Welfare (MHLW) , Japan
  • Hiroshi  Negishi
    Hiroshi Negishi Regulatory Scientist, Therapeutic Area Regulatory
    Eli Lilly Japan K.K., Japan
  • Junichi  Nishino, MSc, RPh
    Junichi Nishino, MSc, RPh Head, Regulatory Operation & Prescribing Information Group, Drug RA Dept.
    Novartis Pharma K.K., Japan
  • Takuya  Oshida, PharmD, MSc
    Takuya Oshida, PharmD, MSc Vice President, Medical Science, Medial Affairs Japan
    Astellas Pharma Inc., Japan
  • Shinichi  Tsuchiwata, MS
    Shinichi Tsuchiwata, MS Senior Manager, Pharmacometrics Group, Clinical Pharmacology
    Pfizer Japan Inc., Japan
  • Atsushi  Tsukamoto, PhD, MSc, PMP
    Atsushi Tsukamoto, PhD, MSc, PMP Senior Director, Project Portfolio Group, Global Project Management Department
    Daiichi Sankyo Co., Ltd., Japan
  • Satoko  Utsunomiya
    Satoko Utsunomiya Japan Development, RA Area Regulatory Strategy & Liaison Group 1
    MSD K.K., Japan
  • Yoshiaki  Uyama, PhD
    Yoshiaki Uyama, PhD Director, Office of Medical Informatics and Epidemiology
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Takeharu  Yamanaka, PhD
    Takeharu Yamanaka, PhD Professor, Department of Biostatistics
    Yokohama City University School of Medicine, Japan
  • Manabu  Yanagisawa, PhD
    Manabu Yanagisawa, PhD Associate Director, Japan Development Regulatory Affairs
    Eisai Co., Ltd., Japan
  • Norie  Yasuda, PhD
    Norie Yasuda, PhD Director, Strategic Business Operations
    Merck Kgaa, Germany
  • Hideki  Hanaoka, MD, PhD
    Hideki Hanaoka, MD, PhD Professor, Clinical Research Center
    Chiba University Hospital, Japan
  • Hironobu  Saito, PhD
    Hironobu Saito, PhD VP, New Drug Regulatory Affairs Dept.
    Daiichi Sankyo Co., Ltd., Japan
Load More